Chemclin Diagnostics Co. Ltd. A (688468) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chemclin Diagnostics Co. Ltd. A (688468) has a cash flow conversion efficiency ratio of 0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥34.41 Million ≈ $5.03 Million USD) by net assets (CN¥1.41 Billion ≈ $206.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 688468 market cap overview for the company's overall valuation and market capitalisation.
Chemclin Diagnostics Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Chemclin Diagnostics Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 688468 stock price and chart for real-time trading data and today's change.
Chemclin Diagnostics Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chemclin Diagnostics Co. Ltd. A ranked by their cash flow conversion efficiency. Review Chemclin Diagnostics Co. Ltd. A (688468) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Siward Crystal Technology Co Ltd
TW:2484
|
0.029x |
|
American Exceptionalism Acquisition Corp. A
NYSE:AEXA
|
0.000x |
|
Kolon Plastics
KO:138490
|
0.036x |
|
American Integrity Insurance Group, Inc.
NYSE:AII
|
0.149x |
|
Xinjiang Haoyuan Natural Gas Co Ltd
SHE:002700
|
0.026x |
|
Beijing ZEHO Waterfront Ecological Environment Treatment Co Ltd
SHG:605069
|
-0.050x |
|
YC Inox Co Ltd
TW:2034
|
0.044x |
|
XMax Inc.
NASDAQ:XWIN
|
-0.140x |
Annual Cash Flow Conversion Efficiency for Chemclin Diagnostics Co. Ltd. A (2017–2025)
The table below shows the annual cash flow conversion efficiency of Chemclin Diagnostics Co. Ltd. A from 2017 to 2025. Also see total assets of Chemclin Diagnostics Co. Ltd. A for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.41 Billion ≈ $206.46 Million |
CN¥93.90 Million ≈ $13.74 Million |
0.067x | -43.88% |
| 2024-12-31 | CN¥1.42 Billion ≈ $207.25 Million |
CN¥167.95 Million ≈ $24.58 Million |
0.119x | -4.83% |
| 2023-12-31 | CN¥1.39 Billion ≈ $203.23 Million |
CN¥173.05 Million ≈ $25.32 Million |
0.125x | -29.66% |
| 2022-12-31 | CN¥1.38 Billion ≈ $202.02 Million |
CN¥244.56 Million ≈ $35.79 Million |
0.177x | +19.94% |
| 2021-12-31 | CN¥1.28 Billion ≈ $187.11 Million |
CN¥188.86 Million ≈ $27.64 Million |
0.148x | -13.75% |
| 2020-12-31 | CN¥887.36 Million ≈ $129.85 Million |
CN¥151.95 Million ≈ $22.24 Million |
0.171x | -26.24% |
| 2019-12-31 | CN¥866.97 Million ≈ $126.87 Million |
CN¥201.27 Million ≈ $29.45 Million |
0.232x | +21.89% |
| 2018-12-31 | CN¥775.38 Million ≈ $113.46 Million |
CN¥147.68 Million ≈ $21.61 Million |
0.190x | -7.66% |
| 2017-12-31 | CN¥647.08 Million ≈ $94.69 Million |
CN¥133.46 Million ≈ $19.53 Million |
0.206x | -- |
About Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more